In this issue:
Nazartinib for treatment-naive EGFR-mutant NSCLC
Adagrasib for advanced KRASG12C tumours, including NSCLC
Clinical impact of STK11 mutation in advanced-stage NSCLC
Lurbinectedin in pretreated SCLC/MPM
De-escalating adjuvant durvalumab duration in stage III NSCLC
Trastuzumab + pertuzumab for advanced pretreated HER2-mutated NSCLC
Nivolumab retreatment in NSCLC after response to prior ICI
Pembrolizumab in NSCLC with poor performance status and high PD-L1 expression
Safety and immunogenicity of mRNA vaccines in ICI-treated lung cancer
Real-world PD-1/PD-L1 inhibitors + RT in metastatic NSCLC
Please login below to download this issue (PDF)